ATG7 Gene Expression as a Novel Tissue Biomarker in Eosinophilic Esophagitis
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Utilizing quantitative reverse transcription-polymerase chain reaction (qRT-PCR), we fi rst evaluated expression of ATG3, ATG6, ATG7, ATG8, and ATG14 in a limited pediatric cohort. A description of these methods is provided in this article's Supplementary Material online. ATG6, ATG7 and ATG8 expressions were elevated in active EoE ( n =5) when compared with normal ( n =5) and EoE remission ( n =5)(data not shown).
Further analysis of a larger pediatric patient cohort ( Table 1 ) including four patient groups, active EoE, EoE remission, gastroesophageal refl ux disease (GERD), and normal, revealed ATG7 upregulation in active EoE ( n =27) compared with non-EoE (i.e., GERD and normal; n =26, P =0.001) and EoE remission ( n =24, P <0.001) ( Figure 1a ). Logistic regression analysis of ATG7 expression adjusted for age revealed an odds ratio of 12.1 (95% CI 3.0, 49.5) for active EoE. Moreover, the area under the receiver-operating characteristic (ROC) curve for the model's predicted value was 0.82 ( Figure 1b ) . Th erefore, ATG7 may serve as a valuable tissue biomarker distinguishing active EoE from remission and non-EoE states. Using 1.6 as an optimal ATG7 expression cutoff point, patients can be classifi ed as active EoE with 48.1% sensitivity, 88% specifi city, and positive and negative predictive values of 68% and 76%, respectively ( Supplementary Table S1 ). Although not a sensitive marker for active EoE, the remarkable specifi city of ATG7 highlights Linear regression analysis revealed only a modest positive correlation between ATG7 and eosinophilic infi ltrate ( r 2 =0.22) (data not shown), identifying ATG7 elevation as a specifi c and an independent marker of active EoE. To further validate this relationship, non-EoE subjects were sub-stratifi ed into normal ( n =20) and PPI-treated GERD ( n =6) cohorts, the latter defi ned by a history of refl ux and histologic non-EoE infl ammatory changes. ATG7 expression remained signifi cantly elevated in active EoE compared with normal ( P =0.001) and GERD ( P =0.017) ( Figure 1a ) .
In summary, we have identifi ed ATG7 as a potential tissue biomarker distinguishing active EoE from normal, EoE remission, and GERD. As subjects in this study were PPI treated, future analysis of GERD subjects before therapy will determine whether ATG7 remains specifi c for active EoE. If this is the case, discovery of a specifi c tissue biomarker for EoE will provide clarity for ambiguous cases and may allow patients to avoid the recommended 8-12-week course of high-dose PPI before esophagogastroduodenoscopy, resulting in earlier diagnosis and treatment.
Identifi cation of autophagy-related EoE biomarkers may also be applicable to speci mens obtained via less invasive methods including the esophageal string test ( 5 ) or cytosponge ( 6 ) . Interestingly, miR-375, a negative regulator of ATG7 expression and autophagy ( 7 ) , is the most downregulated microRNA in esophageal biopsies from active EoE subjects ( 8 ) ; however, the functional relationship between miR-375 and autophagy/ATG7 in EoE remains to be elucidated. Future studies will also assess ATG7 as a prognostic marker interpreted in the context of patient age, disease course, and therapeutic response.
